AR079529A1 - Derivados arilo y heteroarilo sustituidos y fundidos como inhibidores de la pi3k - Google Patents
Derivados arilo y heteroarilo sustituidos y fundidos como inhibidores de la pi3kInfo
- Publication number
- AR079529A1 AR079529A1 ARP100104746A ARP100104746A AR079529A1 AR 079529 A1 AR079529 A1 AR 079529A1 AR P100104746 A ARP100104746 A AR P100104746A AR P100104746 A ARP100104746 A AR P100104746A AR 079529 A1 AR079529 A1 AR 079529A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- nrc5rd5
- independently selected
- nrc5c
- haloalkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Estos compuestos modulan la actividad de las fosfoinositida 3-quinasas (PI3Ks) y son de utilidad en el tratamiento de las enfermedades asociadas con la actividad de las PI3Ks, lo que, por ejemplo, incluye los trastornos inflamatorios, los trastornos inmunologicos, el cáncer y otras enfermedades. Reivindicacion 1: Se reivindica un compuesto de la formula (1) o una sal farmacéuticamente aceptable del mismo; donde el símbolo ôOö indica que el anillo es aromático; Z es O, S o NRA; Cy es cicloalquilo, heterocicloalquilo, arilo o heteroarilo, cada uno opcionalmente sustituido con 1, 2, 3, 4 o 5 grupos RC independientemente seleccionados; cada RC es seleccionado de manera independiente a partir de halo, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, haloalquilo C1-6, halosulfanilo, arilo, cicloalquilo, heteroarilo, heterocicloalquilo, CN, NO2, ORa, SRa, C(O)Rb, C(O)NRcRd, C(O)ORa, OC(O)Rb, OC(O)NRcRd, NRcRd, NRcC(O)Rb, NRcC(O)ORa, NRcC(O)NRcRd, C(=NRe)Rb, C(=NRe)NRcRd, NRcC(=NRe)NRcRd, NRcS(O)Rb, NRcS(O)2Rb, NRcS(O)2NRcRd, S(O)Rb, S(O)NRcRd, S(O)2Rb y S(O)2NRcRd; donde el alquilo C1-6, alquenilo C2-6, alquinilo C2-6, haloalquilo C1-6, arilo, cicloalquilo, heteroarilo y heterocicloalquilo son cada uno opcionalmente sustituidos con 1, 2, 3, 4 o 5 sustituyentes seleccionados de manera independiente a partir de halo, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, haloalquilo C1-6, halosulfanilo, CN, Cy1, NO2, ORa, SRa, C(O)Rb, C(O)NRcRd, C(O)ORa, OC(O)Rb, OC(O)NRcRd, C(=NRe)NRcRd, NRcC(=NRe)NRcRd, NRcRd, NRcC(O)Rb, NRcC(O)ORa, NRcC(O)NRcRd, NRcS(O)Rb, NRcS(O)2Rb, NRcS(O)2NRcRd, S(O)Rb, S(O)NRcRd, S(O)2Rb y S(O)2NRcRd; W es CR3 o N; V es CR4 o N; X es CR5; Y es CR6 o N; y U es CR7 o N; o W es CR3 o N; V es CR4 o N; X es O o S; Y está ausente; y U es CR7 o N; o W es CR3 o N; V es N; X es CR5; Y está ausente; y U es NRA1; o W es CR3 o N; V es O o S; X es CR5; Y está ausente; y U es CR7 o N; con la salvedad que cuando Y esté presente, al menos uno de V, Y y U no es N; R1 es seleccionado de manera independiente a partir de H, alquilo C1-6, haloalquilo C1-6, alquenilo C2-6 y alquinilo C2-6 donde el alquilo C1-6, haloalquilo C1-6, alquenilo C2-6 y alquinilo C2-6 son cada uno opcionalmente sustituidos con 1, 2, 3 o 4 sustituyentes seleccionados de manera independiente a partir de halo, OH, CN, NR1+R2+, alcoxi C1-6, haloalcoxi C1-6, tio, alquiltio C1-6, alquilsulfinilo C1-6, alquilsulfonilo C1-6, carbamilo, alquilcarbamilo C1-6, di(alquil C1-6)carbamilo, carboxi, alquilcarbonoilo C1-6, alcoxi carbonoilo C1-6 y alquilcarbonoilamino C1-6; cada R1+ y R2+ es seleccionado de manera independiente a partir de H y alquilo C1-6; o cualquier R1+ y R2+, conjuntamente con el átomo de N al cual se encuentran acoplados, forman un grupo heterocicloalquilo de 3, 4, 5, 6 o 7 miembros, el cual es opcionalmente sustituido con 1, 2, 3 o 4 sustituyentes seleccionados de manera independiente a partir de alquilo C1-6; R2, R3, R4, R5, R6 y R7 son cada uno seleccionado de manera independiente a partir de H, OH, NO2, CN, halo, alquilo C1-6, alquinilo C1-6, cicloalquilo C3-7, haloalquilo C1-6, alcoxi C1-6, haloalcoxi C1-6, amino, alquilamino C1-6, di(alquil C1-6)amino, tio, alquiltio C1-6, alquilsulfinilo C1-6, alquilsulfonilo C1-6, carbamilo, alquilcarbamilo C1-6, di(alquil C1-6)carbamilo, carboxi, alquilcarbonoilo C1-6 y alcoxi carbonoilo C1-6; Ar es un heteroarilo, sustituido con 1, 2, 3, 4 o 5 grupos RD independientemente seleccionados; cada RD es seleccionado de manera independiente a partir de H, -(alquil C1-4)r-Cy1, halo, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, haloalquilo C1-6, halosulfanilo, CN, NO2, ORa1, SRa1, C(O)Rb1, C(O)NRc1Rd1, C(O)ORa1, OC(O)Rb1, OC(O)NRc1Rd1, C(=NRe)NRc1Rd1, NRc1C(=NRe)NRc1Rd1, NRc1Rd1, NRc1C(O)Rb1, NRc1C(O)ORa1, NRc1C(O)NRc1Rd1, NRc1S(O)Rb1, NRc1S(O)2Rb1, NRc1S(O)2NRc1Rd1, S(O)Rb1, S(O)NRc1Rd1, S(O)2Rb1 y S(O)2NRc1Rd1; RA es seleccionado a partir de H, alquilo C1-6, alquenilo C2-6 y alquinilo C2-6, RA1 es seleccionado a partir de H, alquilo C1-6, alquenilo C2-6 y alquinilo C2-6; cada Cy1 independientemente representa arilo, heteroarilo, cicloalquilo, o heterocicloalquilo, cada uno opcionalmente sustituido por 1, 2, 3, 4 o 5 sustituyentes seleccionados de manera independiente a partir de halo, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, haloalquilo C1-6, halosulfanilo, CN, NO2, ORa1, SRa1, C(O)Rb1, C(O)NRc1Rd1, C(O)ORa1, OC(O)Rb1, OC(O)NRc1Rd1, C(=NRe)NRc1Rd1, NRc1C(=NRe)NRc1Rd1, NRc1Rd1, NRc1C(O)Rb1, NRc1C(O)ORa1, NRc1C(O)NRc1Rd1, NRc1S(O)Rb1, NRc1S(O)2Rb1, NRc1S(O)2NRc1Rd1, S(O)Rb1, S(O)NRc1Rd1, S(O)2Rb1 y S(O)2NRc1Rd1; cada Ra, Rb, Rc y Rd es seleccionado de manera independiente a partir de H, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, arilo, cicloalquilo, heteroarilo, heterocicloalquilo, arilalquilo, heteroarilalquilo, cicloalquilalquilo y heterocicloalquilalquilo, donde el alquilo C1-6, alquenilo C2-6, alquinilo C2-6, arilo, cicloalquilo, heteroarilo, heterocicloalquilo, arilalquilo, heteroarilalquilo, cicloalquilalquilo o heterocicloalquilalquilo es opcionalmente sustituido con 1, 2, 3, 4 o 5 sustituyentes seleccionados de manera independiente a partir de alquilo C1-6, haloalquilo C1-6, halo, CN, ORa5, SRa5, C(O)Rb5, C(O)NRc5Rd5, C(O)ORa5, OC(O)Rb5, OC(O)NRc5Rd5, NRc5Rd5, NRc5C(O)Rb5, NRc5C(O)NRc5Rd5, NRc5C(O)ORa5, C(=NRf)NRc5Rd5, NRc5C(=NRf)NRc5Rd5, S(O)Rb5, S(O)NRc5Rd5, S(O)2Rb5, NRc5S(O)2Rb5, NRc5S(O)2NRc5Rd5 y S(O)2NRc5Rd5; o cualquier Rc y Rd, conjuntamente con el átomo de N al cual se encuentran acoplados, forman un grupo heterocicloalquilo de 3, 4, 5, 6 o 7 miembros o un grupo heteroarilo, cada uno opcionalmente sustituido con 1, 2 o 3 sustituyentes seleccionados de manera independiente a partir de alquilo C1-6, haloalquilo C1-6, halo, CN, ORa5, SRa5, C(O)Rb5, C(O)NRc5Rd5, C(O)ORa5, OC(O)Rb5, OC(O)NRc5Rd5, NRc5Rd5, NRc5C(O)Rb5, NRc5C(O)NRc5Rd5, NRc5C(O)ORa5, C(=NRf)NRc5Rd5, NRc5C(=NRf)NRc5Rd5, S(O)Rb5, S(O)NRc5Rd5, S(O)2Rb5, NRc5S(O)2Rb5, NRc5S(O)2NRc5Rd5 y S(O)2NRc5Rd5; cada Re y Rf es seleccionado de manera independiente a partir de H, alquilo C1-6, CN, ORa5, SRb5, S(O)2Rb5, C(O)Rb5, S(O)2NRc5Rd5 y C(O)NRc5Rd5; cada Ra1, Rb1, Rc1 y Rd1 es seleccionado de manera independiente a partir de H, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, arilo, cicloalquilo, heteroarilo, heterocicloalquilo, arilalquilo, heteroarilalquilo, cicloalquilalquilo y heterocicloalquilalquilo, donde el alquilo C1-6, alquenilo C2-6, alquinilo C2-6, arilo, cicloalquilo, heteroarilo, heterocicloalquilo, arilalquilo, heteroarilalquilo, cicloalquilalquilo o heterocicloalquilalquilo es opcionalmente sustituido con 1, 2, 3, 4 o 5 sustituyentes seleccionados de manera independiente a partir de alquilo C1-6, haloalquilo C1-6, halo, CN, ORa5, SRa5, C(O)Rb5, C(O)NRc5Rd5, C(O)ORa5, OC(O)Rb5, OC(O)NRc5Rd5, NRc5Rd5, NRc5C(O)Rb5, NRc5C(O)NRc5Rd5, NRc5C(O)ORa5, C(=NRf)NRc5Rd5, NRc5C(=NRf)NRc5Rd5, S(O)Rb5, S(O)NRc5Rd5, S(O)2Rb5, NRc5S(O)2Rb5, NRc5S(O)2NRc5Rd5 y S(O)2NRc5Rd5; o cualquier Rc1 y Rd1, conjuntamente con el átomo de N al cual se encuentran acoplados, forman un grupo heterocicloalquilo de 3, 4, 5, 6 o 7 miembros o un grupo heteroarilo, cada uno opcionalmente sustituido con 1, 2 o 3 sustituyentes seleccionados de manera independiente a partir de alquilo C1-6, haloalquilo C1-6, halo, CN, ORa5, SRa5, C(O)Rb5, C(O)NRc5Rd5, C(O)ORa5, OC(O)Rb5, OC(O)NRc5Rd5, NRc5Rd5, NRc5C(O)Rb5, NRc5C(O)NRc5Rd5, NRc5C(O)ORa5, C(=NRf)NRc5Rd5, NRc5C(=NRf)NRc5Rd5, S(O)Rb5, S(O)NRc5Rd5, S(O)2Rb5, NRc5S(O)2Rb5, NRc5S(O)2NRc5Rd5 y S(O)2NRc5Rd5; cada Ra5, Rb5, Rc5 y Rd5 es seleccionado de manera independiente a partir de H, alquilo C1-6, haloalquilo C1-6, alquenilo C2-6, alquinilo C2-6, arilo, cicloalquilo, heteroarilo, heterocicloalquilo, arilalquilo, heteroarilalquilo, cicloalquilalquilo y heterocicloalquilalquilo, donde el alquilo C1-6, haloalquilo C1-6, alquenilo C2-6, alquinilo C2-6, arilo, cicloalquilo, heteroarilo, heterocicloalquilo, arilalquilo, heteroarilalquilo, cicloalquilalquilo o heterocicloalquilalquilo es opcionalmente sustituido con 1, 2 o 3 sustituyentes seleccionados de manera independiente a partir de OH, CN, amino, halo, alquilo C1-6, alcoxi C1-6, alquiltio C1-6, alquilamino C1-6, di(alquil C1-6)amino, haloalquilo C1-6 y haloalcoxi C1-6, o cualquier Rc5 y Rd5, conjuntamente con el átomo de N al cual se encuentran acoplados, forman un grupo heterocicloalquilo de 3, 4, 5, 6 o 7 miembros o grupo heteroarilo, cada uno opcionalmente sustituido con 1, 2 o 3 sustituyentes seleccionados de manera independiente a partir de OH, CN, amino, halo, alquilo C1-6, alcoxi C1-6, alquiltio C1-6, alquilamino C1-6, di(alquil C1-6)amino, haloalquilo C1-6 y haloalcoxi C1-6; y r es igual a 0 o 1; con la salvedad que el compuesto es distinto a: 2-((1-(9H-fluoren-9-il)naftalen-2-il)metiltio)piridina; y 7'-((1H-benzo[d]imidazol-6-ilamino)metil)-N-metil-6,8'-biquinazolin-2-amina; o una sal farmacéuticamente aceptable del mismo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US28790409P | 2009-12-18 | 2009-12-18 | |
US35877510P | 2010-06-25 | 2010-06-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR079529A1 true AR079529A1 (es) | 2012-02-01 |
Family
ID=43606442
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP100104746A AR079529A1 (es) | 2009-12-18 | 2010-12-17 | Derivados arilo y heteroarilo sustituidos y fundidos como inhibidores de la pi3k |
Country Status (4)
Country | Link |
---|---|
US (1) | US8680108B2 (es) |
AR (1) | AR079529A1 (es) |
TW (1) | TW201130842A (es) |
WO (1) | WO2011075630A1 (es) |
Families Citing this family (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5789252B2 (ja) | 2009-05-07 | 2015-10-07 | インテリカイン, エルエルシー | 複素環式化合物およびその使用 |
PL2448938T3 (pl) | 2009-06-29 | 2014-11-28 | Incyte Holdings Corp | Pirymidynony jako inhibitory PI3K |
US8759359B2 (en) * | 2009-12-18 | 2014-06-24 | Incyte Corporation | Substituted heteroaryl fused derivatives as PI3K inhibitors |
EP2345643A1 (en) * | 2009-12-29 | 2011-07-20 | Polichem S.A. | New tertiary 8-hydroxyquinoline-7-carboxamide derivatives and uses thereof |
WO2011130342A1 (en) | 2010-04-14 | 2011-10-20 | Incyte Corporation | FUSED DERIVATIVES AS ΡI3Κδ INHIBITORS |
US9062055B2 (en) | 2010-06-21 | 2015-06-23 | Incyte Corporation | Fused pyrrole derivatives as PI3K inhibitors |
US20140031355A1 (en) * | 2010-11-04 | 2014-01-30 | Amgen Inc. | Heterocyclic compounds and their uses |
WO2012064973A2 (en) | 2010-11-10 | 2012-05-18 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
JP5961187B2 (ja) | 2010-12-20 | 2016-08-02 | インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation | Pi3k阻害剤としてのn−(1−(置換フェニル)エチル)−9h−プリン−6−アミン |
US9108984B2 (en) | 2011-03-14 | 2015-08-18 | Incyte Corporation | Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors |
US9126948B2 (en) | 2011-03-25 | 2015-09-08 | Incyte Holdings Corporation | Pyrimidine-4,6-diamine derivatives as PI3K inhibitors |
HUE030869T2 (en) | 2011-09-02 | 2017-06-28 | Incyte Holdings Corp | Heterocyclic amines as inhibitors of PI3K |
BR112014014327A2 (pt) | 2011-12-15 | 2017-06-13 | Novartis Ag | uso de inibidores da atividade ou função de pi3k |
WO2013090725A1 (en) * | 2011-12-15 | 2013-06-20 | Philadelphia Health & Education Corporation | NOVEL PI3K p110 INHIBITORS AND METHODS OF USE THEREOF |
AR090548A1 (es) | 2012-04-02 | 2014-11-19 | Incyte Corp | Azaheterociclobencilaminas biciclicas como inhibidores de pi3k |
JP6434416B2 (ja) | 2012-11-08 | 2018-12-05 | ライゼン・ファーマシューティカルズ・エスアー | PDE4阻害剤とPI3δ阻害剤または二重PI3δ−γキナーゼ阻害剤とを含有する薬学的組成物 |
EP2920172B1 (en) * | 2012-11-16 | 2019-12-25 | Merck Sharp & Dohme Corp. | Purine inhibitors of human phosphatidylinositol 3-kinase delta |
JP6437452B2 (ja) | 2013-01-14 | 2018-12-12 | インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation | Pimキナーゼ阻害剤として有用な二環式芳香族カルボキサミド化合物 |
MX2015009057A (es) | 2013-01-15 | 2015-10-05 | Incyte Corp | Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de cinasa pim. |
TWI736135B (zh) | 2013-03-01 | 2021-08-11 | 美商英塞特控股公司 | 吡唑并嘧啶衍生物治療PI3Kδ相關病症之用途 |
TW201605866A (zh) | 2013-08-23 | 2016-02-16 | 英塞特公司 | 可用作pim激酶抑制劑之呋喃并-及噻吩并-吡啶甲醯胺化合物 |
UA119767C2 (uk) | 2014-04-08 | 2019-08-12 | Інсайт Корпорейшн | Лікування b-клітинних злоякісних новоутворень із застосуванням комбінації інгібіторів jak та pi3k |
WO2015191677A1 (en) | 2014-06-11 | 2015-12-17 | Incyte Corporation | Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors |
US9822124B2 (en) | 2014-07-14 | 2017-11-21 | Incyte Corporation | Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors |
US9580418B2 (en) | 2014-07-14 | 2017-02-28 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
US9637488B2 (en) | 2015-01-29 | 2017-05-02 | Fuqiang Ruan | Heterocyclic compounds as inhibitors of class I PI3KS |
WO2016130501A1 (en) | 2015-02-09 | 2016-08-18 | Incyte Corporation | Aza-heteroaryl compounds as pi3k-gamma inhibitors |
AU2016222556B2 (en) | 2015-02-27 | 2020-08-27 | Incyte Holdings Corporation | Salts of Pl3K inhibitor and processes for their preparation |
WO2016183071A1 (en) | 2015-05-11 | 2016-11-17 | Incyte Corporation | Hetero-tricyclic compounds and their use for the treatment of cancer |
WO2016183063A1 (en) | 2015-05-11 | 2016-11-17 | Incyte Corporation | Crystalline forms of a pi3k inhibitor |
WO2016183060A1 (en) | 2015-05-11 | 2016-11-17 | Incyte Corporation | Process for the synthesis of a phosphoinositide 3-kinase inhibitor |
US9540347B2 (en) | 2015-05-29 | 2017-01-10 | Incyte Corporation | Pyridineamine compounds useful as Pim kinase inhibitors |
WO2017000125A1 (en) * | 2015-06-29 | 2017-01-05 | Merck Sharp & Dohme Corp. | Purine inhibitors of human phosphatidylinositol 3-kinase delta |
US9708333B2 (en) | 2015-08-12 | 2017-07-18 | Incyte Corporation | Fused bicyclic 1,2,4-triazine compounds as TAM inhibitors |
WO2017035366A1 (en) | 2015-08-26 | 2017-03-02 | Incyte Corporation | Pyrrolopyrimidine derivatives as tam inhibitors |
AR105967A1 (es) | 2015-09-09 | 2017-11-29 | Incyte Corp | Sales de un inhibidor de pim quinasa |
WO2017059251A1 (en) | 2015-10-02 | 2017-04-06 | Incyte Corporation | Heterocyclic compounds useful as pim kinase inhibitors |
AR106595A1 (es) | 2015-11-06 | 2018-01-31 | Incyte Corp | COMPUESTOS HETEROCÍCLICOS COMO INHIBIDORES DE PI3K-g |
US20170190689A1 (en) | 2016-01-05 | 2017-07-06 | Incyte Corporation | Pyridine and pyridimine compounds as pi3k-gamma inhibitors |
PE20190175A1 (es) | 2016-03-28 | 2019-02-01 | Incyte Corp | Compuestos de pirrolotriazina como inhibidores de tam |
TW201803871A (zh) | 2016-06-24 | 2018-02-01 | 英塞特公司 | 作為PI3K-γ抑制劑之雜環化合物 |
KR101798840B1 (ko) | 2017-05-17 | 2017-11-17 | 주식회사 레고켐 바이오사이언스 | 신규 오토탁신 저해 화합물 및 이를 함유하는 약제학적 조성물 |
KR20200088308A (ko) | 2017-09-27 | 2020-07-22 | 인사이트 코포레이션 | Tam 억제제로서 유용한 피롤로트리아진 유도체의 염 |
JP7244504B2 (ja) | 2017-10-18 | 2023-03-22 | インサイト・コーポレイション | PI3K-γ阻害剤としての三級ヒドロキシ基で置換された縮合イミダゾール誘導体 |
AR113922A1 (es) | 2017-12-08 | 2020-07-01 | Incyte Corp | Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas |
JP2021515767A (ja) | 2018-03-07 | 2021-06-24 | バイエル・アクチエンゲゼルシヤフト | Erk5阻害剤の同定及び使用 |
WO2019232188A1 (en) | 2018-06-01 | 2019-12-05 | Incyte Corporation | Dosing regimen for the treatment of pi3k related disorders |
AR117600A1 (es) | 2018-06-29 | 2021-08-18 | Incyte Corp | Formulaciones de un inhibidor de axl / mer |
PT3847175T (pt) | 2018-09-05 | 2024-04-16 | Incyte Corp | Formas cristalinas de um inibidor da fosfoinositídeo 3-quinase (pi3k) |
WO2020077174A1 (en) * | 2018-10-12 | 2020-04-16 | Board Of Regents Of The University Of Nebraska | Phosphodiesterase inhibitors |
WO2020102198A1 (en) | 2018-11-13 | 2020-05-22 | Incyte Corporation | Heterocyclic derivatives as pi3k inhibitors |
WO2020102216A1 (en) | 2018-11-13 | 2020-05-22 | Incyte Corporation | Substituted heterocyclic derivatives as pi3k inhibitors |
US11161838B2 (en) | 2018-11-13 | 2021-11-02 | Incyte Corporation | Heterocyclic derivatives as PI3K inhibitors |
US20230060425A1 (en) | 2019-02-26 | 2023-03-02 | Bayer Aktiengesellschaft | Fused bicyclic heterocycle derivatives as pesticides |
TW202114681A (zh) | 2019-07-02 | 2021-04-16 | 美商eFFECTOR醫療公司 | 轉譯抑制劑及其用途 |
WO2021257863A1 (en) | 2020-06-19 | 2021-12-23 | Incyte Corporation | Pyrrolotriazine compounds as jak2 v617f inhibitors |
US11691971B2 (en) | 2020-06-19 | 2023-07-04 | Incyte Corporation | Naphthyridinone compounds as JAK2 V617F inhibitors |
WO2022006457A1 (en) | 2020-07-02 | 2022-01-06 | Incyte Corporation | Tricyclic urea compounds as jak2 v617f inhibitors |
WO2022006456A1 (en) | 2020-07-02 | 2022-01-06 | Incyte Corporation | Tricyclic pyridone compounds as jak2 v617f inhibitors |
WO2022046989A1 (en) | 2020-08-27 | 2022-03-03 | Incyte Corporation | Tricyclic urea compounds as jak2 v617f inhibitors |
US11919908B2 (en) | 2020-12-21 | 2024-03-05 | Incyte Corporation | Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors |
US11958861B2 (en) | 2021-02-25 | 2024-04-16 | Incyte Corporation | Spirocyclic lactams as JAK2 V617F inhibitors |
TW202320787A (zh) * | 2021-08-11 | 2023-06-01 | 大陸商泰州億騰景昂藥業股份有限公司 | 一種周期蛋白依賴性激酶抑制劑 |
Family Cites Families (135)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3169967A (en) * | 1957-11-14 | 1965-02-16 | Ciba Geigy Corp | Methyl o-lower alkanoyl-reserpates |
US3037980A (en) * | 1955-08-18 | 1962-06-05 | Burroughs Wellcome Co | Pyrrolopyrimidine vasodilators and method of making them |
US3506643A (en) * | 1966-12-09 | 1970-04-14 | Max Thiel | N**6-aralkyl-adenosine derivatives |
DE2139107A1 (de) | 1971-08-04 | 1973-02-15 | Merck Patent Gmbh | Heterocyclisch substituierte adenosinverbindungen |
US3962443A (en) * | 1972-08-14 | 1976-06-08 | Dainippon Pharmaceutical Co., Ltd. | Antibacterial pharmaceutical compositions and processes for preparation thereof |
DE2248232A1 (de) | 1972-10-02 | 1974-04-11 | Basf Ag | 4-thiopyrimido eckige klammer auf 4,5-d eckige klammer zu pyrimidine |
AR204003A1 (es) | 1973-04-03 | 1975-11-12 | Dainippon Pharmaceutical Co | Procedimiento para preparar compuestos derivados del acido 2-(1-piperazinil)-5-oxopirido-(2,3-d)pirimidino-6-carboxilico y sus sales farmaceuticamente aceptables |
US3862189A (en) * | 1973-08-14 | 1975-01-21 | Warner Lambert Co | Aralkyl-substituted purines and pyrimidines as antianginal bronchodilator agents |
US3936454A (en) * | 1973-08-14 | 1976-02-03 | Warner-Lambert Company | 5-Amino-4-chloro-6-(substituted amino)-pyrimidines |
DK3375A (es) | 1974-01-25 | 1975-09-15 | Ciba Geigy Ag | |
JPS58162949A (ja) * | 1982-03-20 | 1983-09-27 | Konishiroku Photo Ind Co Ltd | ハロゲン化銀カラ−写真感光材料 |
JPS6190153A (ja) * | 1984-10-09 | 1986-05-08 | Fuji Photo Film Co Ltd | ハロゲン化銀写真感光材料の処理方法 |
JPS6310746A (ja) * | 1986-07-01 | 1988-01-18 | Tanabe Seiyaku Co Ltd | ナフタレン誘導体 |
CA1324609C (en) | 1986-07-30 | 1993-11-23 | Eastman Kodak Company | Photographic element and process |
US4861701A (en) * | 1987-10-05 | 1989-08-29 | Eastman Kodak Company | Photographic element and process comprising a compound which comprises two timing groups in sequence |
AT388372B (de) | 1987-10-08 | 1989-06-12 | Tanabe Seiyaku Co | Neue naphthalinderivate und sie enthaltende pharmazeutika |
WO1989008113A1 (fr) * | 1988-03-02 | 1989-09-08 | Yoshitomi Pharmaceutical Industries, Ltd. | COMPOSES DE 3,4-DIHYDROTHIENO[2,3-d]PYRIMIDINE ET LEURS APPLICATIONS PHARMACOLOGIQUES |
US5208250A (en) * | 1988-05-25 | 1993-05-04 | Warner-Lambert Company | Known and selected novel arylmethylenyl derivatives of thiazolidinones, imidazolidinones and oxazolidinones useful as antiallergy agents and anti-inflammatory agents |
JPH07107055B1 (es) * | 1990-04-25 | 1995-11-15 | ||
SU1712359A1 (ru) | 1990-05-07 | 1992-02-15 | Уфимский Нефтяной Институт | Гидрохлорид 8 @ -гидроксихинолинового эфира 8-гидроксихинолин-7-карбоновой кислоты, в качестве бактерицида дл подавлени сульфатвосстанавливающих бактерий и культур РSеUDомоNаS и АRтнRовастеR |
US5480883A (en) * | 1991-05-10 | 1996-01-02 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
IL101860A0 (en) * | 1991-05-31 | 1992-12-30 | Ici Plc | Heterocyclic derivatives |
JP3108483B2 (ja) * | 1991-09-30 | 2000-11-13 | 日清製粉株式会社 | インドール誘導体およびこれを有効成分とする抗潰瘍薬 |
US5521184A (en) | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
FR2714907B1 (fr) * | 1994-01-07 | 1996-03-29 | Union Pharma Scient Appl | Nouveaux dérivés de l'Adénosine, leurs procédés de préparation, compositions pharmaceutiques les contenant. |
US6342501B1 (en) * | 1994-02-25 | 2002-01-29 | The Regents Of The University Of Michigan | Pyrrolo[2,3-d] pyrimidines as antiviral agents |
JPH09176162A (ja) * | 1995-12-22 | 1997-07-08 | Toubishi Yakuhin Kogyo Kk | チアゾリジンジオン誘導体及びその製造法並びにそれを含む医薬組成物 |
AU698419B2 (en) * | 1996-07-03 | 1998-10-29 | Dainippon Sumitomo Pharma Co., Ltd. | A novel purine derivative |
US5866702A (en) * | 1996-08-02 | 1999-02-02 | Cv Therapeutics, Incorporation | Purine inhibitors of cyclin dependent kinase 2 |
US6630496B1 (en) * | 1996-08-26 | 2003-10-07 | Genetics Institute Llc | Inhibitors of phospholipase enzymes |
CA2309350C (en) * | 1997-11-12 | 2007-04-03 | Mitsubishi Chemical Corporation | Purine derivatives and medicaments comprising the same as active ingredient |
TW572758B (en) * | 1997-12-22 | 2004-01-21 | Sumitomo Pharma | Type 2 helper T cell-selective immune response inhibitors comprising purine derivatives |
US6828344B1 (en) * | 1998-02-25 | 2004-12-07 | Genetics Institute, Llc | Inhibitors of phospholipase enzymes |
US6479487B1 (en) * | 1998-02-26 | 2002-11-12 | Aventis Pharmaceuticals Inc. | 6, 9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines |
CZ20003960A3 (cs) * | 1998-05-04 | 2002-04-17 | Zentaris Ag | Deriváty indolu a jejich pouľití pro léčení maligních a jiných chorob vyvolaných patologickou proliferací buněk |
JP4549534B2 (ja) * | 1998-05-26 | 2010-09-22 | 中外製薬株式会社 | 複素環を有するインドール誘導体及びモノ又はジアザインドール誘導体 |
JP3997651B2 (ja) | 1998-06-24 | 2007-10-24 | コニカミノルタホールディングス株式会社 | 新規色素及び画像記録材料及び感熱転写材料及びインクジェット記録液 |
DE69942097D1 (de) | 1998-08-11 | 2010-04-15 | Novartis Ag | Isochinoline derivate mit angiogenesis-hemmender wirkung |
AU4963999A (en) | 1998-08-25 | 2000-03-14 | Uab Research Foundation, The | Inhibitors of bacterial nad synthetase |
US6133031A (en) | 1999-08-19 | 2000-10-17 | Isis Pharmaceuticals Inc. | Antisense inhibition of focal adhesion kinase expression |
GB9905075D0 (en) | 1999-03-06 | 1999-04-28 | Zeneca Ltd | Chemical compounds |
JP2000281654A (ja) | 1999-03-26 | 2000-10-10 | Tanabe Seiyaku Co Ltd | イソキノリン誘導体 |
DE19932571A1 (de) * | 1999-07-13 | 2001-01-18 | Clariant Gmbh | Verfahren zur Herstellung von Biarylen unter Palladophosphacyclobutan-Katalyse |
JP2001151771A (ja) | 1999-09-10 | 2001-06-05 | Kyowa Hakko Kogyo Co Ltd | 含窒素芳香族複素環誘導体 |
GB0004890D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
EP1138328A1 (en) | 2000-03-29 | 2001-10-04 | Eli Lilly And Company Limited | Naphthalene derivatives as CNS drugs |
US6667300B2 (en) * | 2000-04-25 | 2003-12-23 | Icos Corporation | Inhibitors of human phosphatidylinositol 3-kinase delta |
PL202623B1 (pl) | 2000-06-28 | 2009-07-31 | Smithkline Beecham Plc | Sposób wytwarzania drobno zmielonego preparatu substancji leczniczej, drobno zmielona substancja lecznicza wytworzona tym sposobem i zawierająca ją kompozycja farmaceutyczna |
ES2261437T3 (es) * | 2000-07-05 | 2006-11-16 | Astellas Pharma Inc. | Derivados de propano-1,3-diona. |
EP2033952B1 (en) * | 2001-03-01 | 2012-08-29 | Shionogi&Co., Ltd. | Nitrogen-containing Heteroaryl compounds having HIV Integrase Inhibitory Activity |
UA76977C2 (en) * | 2001-03-02 | 2006-10-16 | Icos Corp | Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers |
WO2002078700A1 (en) * | 2001-03-30 | 2002-10-10 | Smithkline Beecham Corporation | Pyralopyridines, process for their preparation and use as therapteutic compounds |
WO2002088124A2 (en) * | 2001-04-27 | 2002-11-07 | Smithkline Beecham Corporation | Pyrazolo'1,5-a!pyridine derivatives |
CZ294535B6 (cs) * | 2001-08-02 | 2005-01-12 | Ústav Experimentální Botaniky Avčr | Heterocyklické sloučeniny na bázi N6-substituovaného adeninu, způsoby jejich přípravy, jejich použití pro přípravu léčiv, kosmetických přípravků a růstových regulátorů, farmaceutické přípravky, kosmetické přípravky a růstové regulátory tyto sloučeniny obsahující |
US8124625B2 (en) * | 2001-09-14 | 2012-02-28 | Shionogi & Co., Ltd. | Method of enhancing the expression of apolipoprotein AI using olefin derivatives |
MXPA04002243A (es) | 2001-09-19 | 2004-06-29 | Aventis Pharma Sa | Compuestos quimicos. |
BR0212829A (pt) * | 2001-09-26 | 2004-08-03 | Bayer Pharmaceuticals Corp | Derivados de 1,8-naftiridina e seu uso para tratar diabetes e distúrbios relacionados |
ATE335490T1 (de) | 2001-10-30 | 2006-09-15 | Novartis Pharma Gmbh | Staurosporin-derivate als hemmer der flt3- rezeptor-tyrosinkinase-wirkung |
US7262164B2 (en) * | 2001-11-09 | 2007-08-28 | Enzon, Inc. | Polymeric thiol-linked prodrugs employing benzyl elimination systems |
TW200301135A (en) * | 2001-12-27 | 2003-07-01 | Otsuka Maryland Res Inst Inc | Pharmaceutical compositions comprising a multifunctional phosphodiesterase inhibitor and an adenosine uptake inhibitor |
ES2291628T3 (es) * | 2002-04-03 | 2008-03-01 | Bristol-Myers Squibb Company | Compuestos triciclicos a base de tiofeno y composiciones farmaceuticas que comprenden dichos compuestos. |
KR20050006221A (ko) * | 2002-05-06 | 2005-01-15 | 제네랩스 테크놀로지스, 인코포레이티드 | C형 간염 바이러스 감염 치료용의 뉴클레오시드 유도체 |
TW200406374A (en) | 2002-05-29 | 2004-05-01 | Novartis Ag | Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases |
GB0215676D0 (en) | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
MXPA05003193A (es) * | 2002-09-27 | 2005-06-08 | Sumitomo Pharma | Compuesto de adenina novedoso y uso del mismo. |
TWI335913B (en) | 2002-11-15 | 2011-01-11 | Vertex Pharma | Diaminotriazoles useful as inhibitors of protein kinases |
EA013811B1 (ru) | 2002-11-21 | 2010-08-30 | Новартис Вэксинес Энд Дайэгностикс, Инк. | 2,4,6-тризамещённые пиримидины, являющиеся ингибиторами фосфотидилинозитол(pi)-3-киназы, и их применение при лечении рака |
UA80767C2 (en) | 2002-12-20 | 2007-10-25 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
JP4500689B2 (ja) * | 2002-12-26 | 2010-07-14 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 選択的エストロゲン受容体モジュレーター |
CZ294538B6 (cs) * | 2002-12-30 | 2005-01-12 | Ústav Experimentální Botaniky Akademie Vědčeské Re | Substituční deriváty N6-benzyladenosinu, způsob jejich přípravy, jejich použití pro přípravu léčiv, kosmetických přípravků a růstových regulátorů, farmaceutické přípravky, kosmetické přípravky a růstové regulátory tyto sloučeniny obsahující |
RU2233842C1 (ru) | 2003-01-13 | 2004-08-10 | Петров Владимир Иванович | Производные пурина, обладающие противовирусной активностью |
GB0305929D0 (en) | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
US7129264B2 (en) * | 2003-04-16 | 2006-10-31 | Bristol-Myers Squibb Company | Biarylmethyl indolines and indoles as antithromboembolic agents |
CA2524376A1 (en) * | 2003-05-05 | 2004-12-16 | Neurogen Corporation | Substituted imidazolopyrazine and triazolopyrazyne derivatives: gabaa receptor ligands |
JP4570015B2 (ja) | 2003-07-14 | 2010-10-27 | クミアイ化学工業株式会社 | 2−イソオキサゾリン誘導体及びそれを有効成分として含有する除草剤 |
WO2005028434A2 (en) * | 2003-09-18 | 2005-03-31 | Conforma Therapeutics Corporation | Novel heterocyclic compounds as hsp90-inhibitors |
AR045944A1 (es) | 2003-09-24 | 2005-11-16 | Novartis Ag | Derivados de isoquinolina 1.4-disustituidas |
JP2007520559A (ja) * | 2004-02-03 | 2007-07-26 | アボット・ラボラトリーズ | 治療薬としてのアミノベンゾオキサゾール類 |
JPWO2005077948A1 (ja) * | 2004-02-16 | 2008-01-10 | 第一製薬株式会社 | 抗真菌作用複素環化合物 |
CN1560035A (zh) * | 2004-03-12 | 2005-01-05 | 沈阳药科大学 | 5-羟基吲哚-3-羧酸脂类衍生物 |
US20070225303A1 (en) * | 2004-03-26 | 2007-09-27 | Haruhisa Ogita | 8-Oxoadenine Compound |
EP1740587A4 (en) * | 2004-04-02 | 2009-07-15 | Adenosine Therapeutics Llc | SELECTIVE ANTAGONISTS OF A2A ADENOSINE RECEPTORS |
US20060074102A1 (en) * | 2004-05-14 | 2006-04-06 | Kevin Cusack | Kinase inhibitors as therapeutic agents |
GB0420719D0 (en) * | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
MX2007004699A (es) * | 2004-10-19 | 2007-06-14 | Novartis Vaccines & Diagnostic | Derivados de indol y bencimidazol. |
EP1807417A2 (en) * | 2004-11-04 | 2007-07-18 | Neurogen Corporation | Pyrazolylmethyl heteroaryl derivatives |
WO2006056399A2 (en) | 2004-11-24 | 2006-06-01 | Novartis Ag | Combinations of jak inhibitors and at least one of bcr-abl, flt-3, fak or raf kinase inhibitors |
AU2006214190A1 (en) * | 2005-02-17 | 2006-08-24 | Icos Corporation | Phosphoinositide 3-kinase inhibitors for inhibiting leukocyte accumulation |
EP1924265A4 (en) * | 2005-08-16 | 2010-06-02 | Genzyme Corp | COMPOUNDS BINDING TO CHEMOKINE RECEPTORS |
US7642270B2 (en) * | 2005-09-14 | 2010-01-05 | Janssen Pharmaceutica N.V. | 5-oxo-5,8-dihydro-pyrido-pyrimidine as inhibitors of c-fms kinase |
JPWO2007034817A1 (ja) * | 2005-09-22 | 2009-03-26 | 大日本住友製薬株式会社 | 新規アデニン化合物 |
GB0520657D0 (en) | 2005-10-11 | 2005-11-16 | Ludwig Inst Cancer Res | Pharmaceutical compounds |
EP1783114A1 (en) | 2005-11-03 | 2007-05-09 | Novartis AG | N-(hetero)aryl indole derivatives as pesticides |
US7557213B2 (en) * | 2005-11-10 | 2009-07-07 | Chemocentryx, Inc. | Substituted quinolones and methods of use |
PE20071025A1 (es) * | 2006-01-31 | 2007-10-17 | Mitsubishi Tanabe Pharma Corp | Compuesto amina trisustituido |
US20080009508A1 (en) * | 2006-07-10 | 2008-01-10 | Lucie Szucova | 6,9-Disubstituted Purine Derivatives And Their Use For Treating Skin |
US20100035756A1 (en) * | 2006-07-12 | 2010-02-11 | Syngenta Limited | Triazolophyridine derivatives as herbicides |
WO2008032033A1 (en) | 2006-09-14 | 2008-03-20 | Astrazeneca Ab | 4-benzimidazolyl-2-morpholino-6-piperazinylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders |
EP1972631A1 (en) | 2007-03-23 | 2008-09-24 | Novartis AG | Imidazopyridazines as PI3K lipid kinase inhibitors |
WO2008055013A2 (en) * | 2006-10-31 | 2008-05-08 | Janssen Pharmaceutica N.V. | 5-oxo-5,8 - dihydro - pyrido - pyrimidines as inhibitors of c-fms kinase |
CN101589046B (zh) * | 2006-12-29 | 2011-09-21 | 弗·哈夫曼-拉罗切有限公司 | 氮杂螺环衍生物 |
US20080194616A1 (en) * | 2007-02-05 | 2008-08-14 | Xenon Pharmaceuticals Inc. | Pyridopyrimidinone compounds useful in treating sodium channel-mediated diseases or conditions |
PE20081887A1 (es) * | 2007-03-20 | 2009-01-16 | Dainippon Sumitomo Pharma Co | Nuevo compuesto de adenina |
UA98955C2 (ru) * | 2007-03-23 | 2012-07-10 | Амген Инк. | Гетероциклические соединения и их применение |
US8039505B2 (en) * | 2007-04-11 | 2011-10-18 | University Of Utah Research Foundation | Compounds for modulating T-cells |
US9603848B2 (en) * | 2007-06-08 | 2017-03-28 | Senomyx, Inc. | Modulation of chemosensory receptors and ligands associated therewith |
US8633186B2 (en) * | 2007-06-08 | 2014-01-21 | Senomyx Inc. | Modulation of chemosensory receptors and ligands associated therewith |
JP2010531304A (ja) * | 2007-06-18 | 2010-09-24 | ユニバーシティ オブ ルイビル リサーチ ファウンデーション、インコーポレイテッド | 抗悪性腫瘍活性を有するpfkfb3阻害物質ファミリー |
CA2691444C (en) * | 2007-06-29 | 2016-06-14 | Gilead Sciences, Inc. | Purine derivatives and their use as modulators of toll-like receptor 7 |
WO2009042294A2 (en) * | 2007-08-10 | 2009-04-02 | Burnham Institute For Medical Research | Tissue-nonspecific alkaline phosphatase (tnap) activators and uses thereof |
JP2009076865A (ja) | 2007-08-29 | 2009-04-09 | Fujifilm Corp | 有機電界発光素子 |
JP2009080233A (ja) | 2007-09-26 | 2009-04-16 | Kyocera Mita Corp | 電子写真感光体 |
CZ300774B6 (cs) * | 2007-10-05 | 2009-08-05 | Univerzita Palackého | Substituované 6-(alkylbenzylamino)purinové deriváty pro použití jako antagonisté cytokininových receptoru a prípravky obsahující tyto slouceniny |
JP2009120686A (ja) | 2007-11-14 | 2009-06-04 | Toyo Ink Mfg Co Ltd | 光重合開始剤、重合性組成物、および重合物の製造方法。 |
CA2709784A1 (en) * | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
WO2009081105A2 (en) * | 2007-12-21 | 2009-07-02 | Ucb Pharma S.A. | Quinoxaline and quinoline derivatives as kinase inhibitors |
US7960397B2 (en) * | 2007-12-28 | 2011-06-14 | Institute Of Experimental Botany, Academy Of Sciences Of The Czech Republic | 6,9-disubstituted purine derivatives and their use as cosmetics and cosmetic compositions |
AU2009211004C1 (en) * | 2008-01-11 | 2013-08-01 | Natco Pharma Limited | Novel pyrazolo [3, 4 -d] pyrimidine derivatives as anti -cancer agents |
US9089572B2 (en) * | 2008-01-17 | 2015-07-28 | California Institute Of Technology | Inhibitors of p97 |
US8026271B2 (en) * | 2008-07-11 | 2011-09-27 | National Health Research Institutes | Formulations of indol-3-yl-2-oxoacetamide compounds |
EP2387575B1 (en) * | 2009-01-15 | 2013-09-04 | Anvyl, LLC | Alpha7 nicotinic acetylcholine receptor allosteric modulators, their derivatives and uses thereof |
JP5789252B2 (ja) * | 2009-05-07 | 2015-10-07 | インテリカイン, エルエルシー | 複素環式化合物およびその使用 |
PL2448938T3 (pl) * | 2009-06-29 | 2014-11-28 | Incyte Holdings Corp | Pirymidynony jako inhibitory PI3K |
ES2644286T3 (es) * | 2009-10-22 | 2017-11-28 | Gilead Sciences, Inc. | Derivados de purina o deazapurina útiles para el tratamiento de (entre otros) infecciones víricas |
US8759359B2 (en) * | 2009-12-18 | 2014-06-24 | Incyte Corporation | Substituted heteroaryl fused derivatives as PI3K inhibitors |
JP2011136925A (ja) | 2009-12-28 | 2011-07-14 | Dainippon Sumitomo Pharma Co Ltd | 含窒素二環性化合物 |
US8633183B2 (en) | 2010-01-26 | 2014-01-21 | Boehringer Ingelheim International Gmbh | 5-alkynyl-pyrimidines |
WO2011130342A1 (en) | 2010-04-14 | 2011-10-20 | Incyte Corporation | FUSED DERIVATIVES AS ΡI3Κδ INHIBITORS |
US9062055B2 (en) * | 2010-06-21 | 2015-06-23 | Incyte Corporation | Fused pyrrole derivatives as PI3K inhibitors |
JP5961187B2 (ja) * | 2010-12-20 | 2016-08-02 | インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation | Pi3k阻害剤としてのn−(1−(置換フェニル)エチル)−9h−プリン−6−アミン |
US9108984B2 (en) | 2011-03-14 | 2015-08-18 | Incyte Corporation | Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors |
US9126948B2 (en) | 2011-03-25 | 2015-09-08 | Incyte Holdings Corporation | Pyrimidine-4,6-diamine derivatives as PI3K inhibitors |
CN103930422A (zh) * | 2011-07-19 | 2014-07-16 | 无限药品股份有限公司 | 杂环化合物及其用途 |
HUE030869T2 (en) * | 2011-09-02 | 2017-06-28 | Incyte Holdings Corp | Heterocyclic amines as inhibitors of PI3K |
AR090548A1 (es) * | 2012-04-02 | 2014-11-19 | Incyte Corp | Azaheterociclobencilaminas biciclicas como inhibidores de pi3k |
-
2010
- 2010-12-17 WO PCT/US2010/060980 patent/WO2011075630A1/en active Application Filing
- 2010-12-17 US US12/972,155 patent/US8680108B2/en active Active
- 2010-12-17 AR ARP100104746A patent/AR079529A1/es unknown
- 2010-12-17 TW TW099144671A patent/TW201130842A/zh unknown
Also Published As
Publication number | Publication date |
---|---|
US20110183985A1 (en) | 2011-07-28 |
WO2011075630A1 (en) | 2011-06-23 |
US8680108B2 (en) | 2014-03-25 |
TW201130842A (en) | 2011-09-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR079529A1 (es) | Derivados arilo y heteroarilo sustituidos y fundidos como inhibidores de la pi3k | |
AR077975A1 (es) | Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina | |
AR081823A1 (es) | DERIVADOS FUSIONADOS COMO INHIBIDORES DE PI3Kd | |
AR077280A1 (es) | Pirimidinonas como inhibidores de pi3k, y composiciones farmaceuticas que los comprenden | |
AR085960A1 (es) | 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2 | |
EA201490272A1 (ru) | Новые 4-пиперидинильные соединения для применения в качестве ингибиторов танкиразы | |
AR083069A1 (es) | Analogos de nucleotidos sustituidos | |
ES2616477T3 (es) | Heterociclaminas como inhibidores de pi3k | |
AR078408A1 (es) | Derivados de indol como moduladores de los crac | |
AR077434A1 (es) | Compuestos para la reduccion de produccion de beta - amiloide | |
AR086983A1 (es) | Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak | |
CO6390038A2 (es) | Derivados de sulfonamida como agentes inductores de apoptosis con selectividad por bcl-2 para el tratamiento de cancer y enfermedades inmunes | |
AR072952A1 (es) | Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso | |
ECSP14013221A (es) | Fenil-3-aza-biciclo [3.1.0] hex-3-il-metanonas y su uso como medicamento. | |
EA201390717A1 (ru) | 3-(аминоарил)пиридиновые соединения | |
AR076008A1 (es) | Derivados de hidroximetil-isoxazol moduladores de receptores gaba a, composiciones farmaceuticas que los contienen, metodo para prepararlos y uso de los mismos para el tratamiento del alzheimer y otros trastornos cognitivos. | |
AR077977A1 (es) | Compuestos y composiciones como inhibidores de cinasa de proteina | |
EA201500298A1 (ru) | Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы | |
AR089781A1 (es) | Fluorometil-5,6-dihidro-4h-[1,3]oxazinas | |
AR087915A1 (es) | N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la bace1 | |
UA108510C2 (en) | Cyclopropane compound | |
EA201170722A1 (ru) | Лактамы в качестве ингибиторов бета-секретазы | |
EA201590438A1 (ru) | 2-оксо-2,3-дигидроиндолы для лечения расстройств центральной нервной системы | |
NZ712660A (en) | Dicarboxylic acid compound | |
EA201001566A1 (ru) | Новый класс спиропиперидинов для лечения нейродегенеративных заболеваний |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |